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ABSTRACT
Triple negative, resistant or metastatic disease are major factors in breast 
cancer mortality, warranting novel approaches. Carbonic anhydrase IX (CAIX) is 
implicated in survival, migration and invasion of breast cancer cells and inhibition 
provides an innovative therapeutic strategy. The efficacy of 5 novel ureido-
substituted sulfamate CAIX inhibitors were assessed in increasingly complex 
breast cancer models, including cell lines in normoxia and hypoxia, 3D spheroids 
and an ex-vivo explant model utilizing fresh biopsy tissue from different breast 
cancer subtypes. CAIX expression was evaluated in a tissue microarray (TMA) 
of 92 paired lymph node and primary breast cancers and 2 inhibitors were 
appraised in vivo using MDA-MB-231 xenografts. FC11409B, FC9398A, FC9403, 
FC9396A and S4 decreased cell proliferation and migration and inhibited 3D 
spheroid invasion. S4, FC9398A and FC9403A inhibited or prevented invasion into 
collagen. FC9403A significantly reversed established invasion whilst FC9398A 
and DTP348 reduced xenograft growth. TMA analysis showed increased CAIX 
expression in triple negative cancers. These data establish CAIX inhibition as a 
relevant therapeutic goal in breast cancer, targeting the migratory, invasive, and 
metastatic potential of this disease. The use of biopsy tissue suggests efficacy 
against breast cancer subtypes, and should provide a useful tool in drug testing 
against invasive cancers.
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INTRODUCTION
A recent analysis by over 100 breast cancer 
specialists emphasized critical gaps in research knowledge 
needed to increase the successful treatment of breast 
cancer. Targeting the tumour microenvironment, novel 
therapies for metastatic and triple negative breast cancer 
and better experimental models that encompass breast 
cancer subtypes were amongst the factors highlighted [1]. 
To address several of these issues, we examined the effect 
of novel inhibitors of carbonic anhydrase IX (CAIX), 
an enzyme involved in pH regulation, on breast cancer 
growth and invasion using a series of increasingly 
complex models.
As solid tumors develop, areas of low oxygen 
tension and acidosis are produced which are associated 
with the development of radiation and chemotherapy 
resistance [2]. Hypoxic conditions activate the 
transcription factor Hypoxia Inducible Factor-1 
(HIF-1), a heterodimer containing HIF-1α and HIF-1β 
subunits [3]. HIF-1α expression is mainly dependent on 
hypoxia since, in the presence of oxygen, it is degraded 
within minutes [4]. However, dysregulation of tumor 
suppressors, oncogenes and growth factor receptor number 
increase the expression of HIF-1α and up-regulation of 
transcriptional targets in normoxic cancer cells [5, 6]. In 
breast cancer, increased HIF-1α expression is associated 
with poor prognosis, since HIF-1 controls expression 
of proteins required for surviva1 in hypoxic and acidic 
conditions [7, 8].
One such protein, CAIX, has been linked to poor 
prognosis and survival of breast cancer patients [9–12]. 
Expression of CAIX is low in normal breast tissue or 
benign lesions, but strongly expressed in 50% of all 
ductal carcinoma in situ (DCIS) of the breast, and in 38% 
of DCIS associated with invasive disease and is present 
mainly in abnormal epithelium in breast carcinoma [9, 13].
The CAIX transmembrane protein consists of a 
proteoglycan-like domain and an intracellular carboxy 
terminal tail which can influence cell-cell adhesion [14], 
and catalyzes the reversible reaction CO2 + H2O → H
+ + 
HCO3
− [15]. This production of protons acidifies the tumor 
microenvironment, while bicarbonate ions are transported 
into the cell maintaining an alkaline intracellular 
pH [16, 17], which may inhibit apoptosis [2, 18].
Hypoxia increases expression of metalloproteinases 
in breast and other cancer cells; these enzymes are activated 
in acidic conditions causing destruction of basement 
membrane components thus enhancing the ability of tumor 
cells to metastasize [18, 19]. Similarly, cell migration 
depends on acidic conditions in lamellipodia, which 
are partially produced by activation of CAIX and its 
interaction with bicarbonate transporters [20]. Since the 
acidic/hypoxic conditions in the tumor microenvironment 
facilitate tumor progression, CAIX plays an important part 
in the acidification of the tumor environment and tumor 
metastasis. Metastatic growth is associated with epithelial 
to mesenchymal transition (EMT) and is strongly linked 
to loss of E-cadherin [21] because hypoxia activates the 
lysyl oxidase-Snail pathway which represses E-cadherin 
expression [22]. Furthermore, CAIX is known to impede 
E-cadherin mediated cell adhesion by decreasing the amount 
of E-cadherin bound to the cytoskeleton [14]. Recent 
studies also demonstrate that CAIX enhances the metastatic 
potential of tumor cells by a mechanism associated with 
decreased Rho-GTPase activity leading to EMT [23].
We and others have been involved in the 
development of novel, more specific CAIX inhibitors as 
a potential, innovative therapeutic strategy for treatment 
of breast cancer and other solid tumors [24–27]. 
However, targeting survival mechanisms involved in 
adaptation to the tumor microenvironment in oncology 
drug development requires culture techniques that 
reproduce these acidic/hypoxic conditions, and therefore 
more appropriate systems are needed to develop these 
approaches. We utilized a range of pre-clinical models 
to assess the effects of these compounds, from cell 
lines cultured in normoxic or hypoxic conditions to 3D 
spheroid culture and xenografts. This approach was 
extended by examining the effects of these compounds 
on the survival and invasion of ex vivo cultures of tumor 
explants from fresh, pre-treatment, breast cancer patient 
biopsies, which more accurately reflect receptor and 
oncogene overexpression and contain stromal elements 
that may affect therapeutic outcomes. This model system 
encompasses the heterogeneity found in breast tumors 
per se, as well as that found between different breast 
cancer subtypes.
Our data using these varied in vitro and in vivo 
experimental systems show that CAIX inhibition has a 
significant effect on migration, invasion and proliferation 
in the common breast cancer subtypes and that CAIX 
expression significantly correlates with metastasis in a 
series of lymph node positive patient breast tumors. This 
suggests that CAIX inhibitors are likely to form a useful 
therapeutic adjunct to conventional adjuvant radiotherapy 
and systemic therapy for breast cancer.
RESULTS
Novel ureido-sulfamate CAIX inhibitors reduce 
cell proliferation in a panel of breast cancer cell 
lines in normoxic and hypoxic conditions
Our previous study evaluating a series of 50 
novel ureido-sulfamate CAIX inhibitors, showed that 
5 compounds could significantly inhibit proliferation of 
several human breast cancer cell lines in both hypoxic 
(0.5% O2) and normoxic conditions (21% O2); these were 
FC11409B, FC9398A, FC9403, FC9396A and S4 (24). 
Their structures are shown in Figure 1A. Ki values for 
these compounds against CAIX and details of synthesis 
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were previously reported [25]. We examined the effects 
of these inhibitors in an expanded panel of breast cancer 
cell lines (Supplementary Table S1) representing the major 
breast cancer subtypes, with variable hormone and growth 
factor receptor expression. The effect of all 5 compounds 
on cell proliferation is illustrated using the MDA-MB-231 
cell line as an example in Figure 1B (normoxia) and 
Figure 1C (hypoxia). Similar data were obtained for all 
cell lines examined. In normoxic conditions the inhibitory 
effect of all 5 compounds on cell proliferation in this cell 
line was highly significant (P < 0.001) at 30 and 100 μM 
except for FC9396A which was significant at 100 μM 
alone and for FC9403 which significantly inhibited 
cell proliferation at 10 μM (Figure 1B). The variation 
in response between some of the cell line panel in 
normoxia is demonstrated in Figure 1D using FC9396A 
as an example. The dose responses demonstrated that 
the IC50 values for each compound varied between cell 
lines in normoxic conditions (Supplementary Table S2). 
However, in hypoxic conditions, the effect of all the 
inhibitors was highly significant (P < 0.001) at 30 and 100 
μM, with cell proliferation almost completely inhibited at 
Figure 1: The anti-proliferative effects of novel ureido-sulfamate CAIX inhibitors on the growth of breast cancer cell 
lines in vitro. A. The structures of the 5 novel ureido-sulfamate CAIX inhibitors, FC9396A, FC9403A, FC9398A, FC11409B, and S4 
used in this study. B. The effect of the CAIX inhibitors, FC9396A, FC9403A, FC9398A, FC11409B, and S4 on the proliferation of MDA-
MD-231 breast cancer cells in normoxia. Compounds were used at concentrations between 3 – 100 μM. Data represents mean of n = 5 
assays; 6 replicates per assay, at day 5. C. The response to the CAIX inhibitors, FC9396A, FC9403A, FC9398A, FC11409B, and S4 on 
the proliferation of MDA-MD-231 breast cancer cells in hypoxia (0.5% O2) Compounds were used at concentrations between 3 – 100 μM. 
n = 2 assays, 6 replicates per assay at day 5. D. The concentration response of a panel of various breast cancer cell lines to the CAIX 
inhibitor FC9396A in normoxic conditions. Compounds were used at concentrations between 3 – 100 μM. n = 3 assays, 6 replicates per 
assay at day 5. E. The anti-proliferative response of a panel of breast cancer cell lines to the CAIX inhibitor FC9398A used at concentrations 
between 3 – 100 μM, in hypoxia (0.5% O2). n = 2 assays, 6 replicates per assay at day 5.
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these concentrations (Figure 1C). The responses to all 
compounds in low oxygen tensions were similar in each 
of the cell lines with IC50 values between 10 and 30 μM. 
For illustration, the variation of response to one inhibitor 
FC9398A under hypoxic conditions in the cell line panel 
is shown in Figure 1E.
The effect of novel CAIX inhibitors on breast 
cancer cell migration in hypoxia and normoxia
The influence of the five CAIX inhibitors on 
migration was assessed using wound healing assays with 
the MDA-MB-231 invasive cell line. The results for S4 
in normoxia (Supplementary Figure S1A) and hypoxia 
(Supplementary Figure S1B) show concentrations of 30 
μM clearly inhibit migration. Supplementary Table S3 
illustrates that these novel CAIX inhibitors reduce the 
migratory capacity of these cells under both normoxic 
and hypoxic conditions, except for FC9396A, which was 
only effective in normoxia. However, MDA-MB-231 
cells migrated into the wound area as single cells, 
making accurate quantitation difficult. Therefore the 
same inhibitors were further assessed using the invasive 
ovarian cell line SKOV3, to determine firstly, that the 
effects on migration/invasion are not specific to the MDA-
MB-231 model alone and also to provide quantitative data 
(Supplementary Figure S1C).
Significant inhibition of motility was observed 
in SKOV-3 cells treated with S4 at 10, 30, and 100 μM 
in normoxic conditions and at 30 and 100 μM in 
hypoxic conditions. FC11409B inhibited migration 
in both normoxia and hypoxia, but only at the highest 
concentrations of 100 μM. FC9396A had little inhibitory 
activity in this assay in normoxic or hypoxic conditions, 
while FC9398A, was effective at 100 μM in normoxia, 
and 30 and 100 μM in hypoxia. FC9403A was equally 
effective regardless of oxygen status at both 30 and 
100 μM. The combined results for this assay suggest 
that the compounds S4 and FC9403A are the most active 
inhibitors of migration.
CAIX expression in breast cancer cell 3D 
spheroids
3D breast cancer spheroids, which contain a 
graduated range of oxygen concentrations, were assessed 
to determine the presence of hypoxic areas and CAIX 
positive staining. The hypoxic core of an MDA-MB-231 
spheroid is shown using ‘Hypoxyprobe’ visualized using 
a fluorescent microscope (Supplementary Figure S2A). 
Similarly, HIF-1α staining is also shown for comparison 
in MDA-MD-231 spheroids (Supplementary Figure S2B). 
Immunohistochemical staining for CAIX in several 
breast cancer cell spheroid models showed that the 
expression of this enzyme is not confined to hypoxic areas 
(Supplementary Figure S2C). Although it has previously 
been reported that CAIX expression is confined to the 
hypoxic cores of 3D spheroids [17], we clearly show 
that in many of our breast cancer cell spheroid models, 
that there is variant expression of CAIX in areas of 
the spheroids that are not hypoxic (Supplementary 
Figure S2C).
The effect of CAIX inhibitors on 3D breast 
spheroid invasion
To examine the ability of the CAIX inhibitors to 
impede invasion of 3D breast cancer cell cultures, MDA-
MB-231 spheroids were embedded in collagen plugs 
containing the CAIX inhibitors at different concentrations 
and examined at 24 and 48 h. A representative experiment 
is shown in Figure 2A (A–H), and results for all 
compounds are shown in Figure 2B. This data reveals 
significant inhibition in the capacity of MDA-MB-231 
spheroids to invade a collagen matrix if treated with S4 
or FC9403A at 30 or 100 μM and FC11409B, FC9398A, 
FC9396A at 100 μM. FC9396A (3 μM) however, 
significantly increased invasion. Although both 2D and 
3D migration/invasion assays showed some inhibitory 
activity for all the active compounds, the results from 
3D spheroid collagen invasion assays confirmed that S4 
and FC9403A are the most active inhibitors of migration/
invasion.
The effect of CAIX inhibitors on growth and 
invasion of tumor explants
To assess the effects of CAIX inhibition in actual 
tumor tissue, ex vivo human breast tumor explants from 
pre-treatment fresh core needle biopsies were examined. 
A representative assay using FC9403A is shown in 
Figure 3A (A–D), after 5 days of culture, and demonstrates 
clear invasion in both the control (A) and 10 μM (B) 
treated explants, while higher concentrations of 30 (C) 
and 100 μM (D) prevented invasion. Figure 3B illustrates 
pooled data from 26 separate biopsy specimens (explant 
number = 214 – 177 per time point) after growth in 
collagen for 15 days with invasion assessed by increased 
area. Although approximately 50% of explants were 
invasive by Day 5, the percentage increase in invasion 
was significantly increased by Day 10. The effect of three 
CAIX inhibitors, S4, FC9403A and FC9398A, on growth 
and invasion were assessed.
The results for S4 (Figure 3C) show at day 5 there 
is no significant growth under any treatment. However by 
day 10 and 15 the higher concentrations of S4 (30 and 
100 μM) have significantly prevented growth and invasion 
of the tumor tissue. Similar results were obtained using the 
compound FC9398A and FC9403A (Figure 3D and 3E). 
Again, by day 15 concentrations of FC9403A from 3 
to 100 μM significantly inhibited explant invasion into 
collagen in comparison with untreated control explants.
Although some explants showed invasive capacity, 
they also demonstrated regression in actual explant 
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size (Figure 4A). These would be considered non-
invasive if explant area measurement was the sole criteria 
used to determine the effects of the CAIX inhibitors 
on invasion. Therefore, to ensure that invasion was 
measured accurately, we recorded whether or not each 
explant invaded collagen when treated with differing 
concentrations of each of the inhibitors (Figure 4B–4E). 
These results depict only whether an explant was scored as 
invasive or non-invasive, regardless of area. Using these 
criteria, all three drugs significantly inhibited invasion 
at 30 and 100 μM, however, invasion was completely 
prevented by FC9403A at these concentrations.
The effect of CAIX inhibitors on reversal of 
explant invasion
To determine whether these compounds could 
also influence established invasive growth, inhibitors 
were added after 15 days to invasive explants and the 
consequences monitored. A representative experiment 
using FC9403A is shown in Figure 5A. Results for 
FC9398A (Figure 5B) indicate that, although invasion has 
not been reversed, the inhibitor has prevented any further 
growth in the invasive front since there is no significant 
difference in invasive area after treatment with drug 
Figure 2: The effect of S4, FC9396A, FC9403A, and FC11409B on the ability of MDA-MB-231 spheroids to invade 
collagen. A. 3D collagen invasion assay. Shown are the results of treating MDA-MB-231 spheroids with the CAIX inhibitor FC11409B 
at time 0 and at 48 h. A, C, E and G are time 0; B, D, F, H, are time 48 hours. A and B are controls; C and D, FC11409B 10 μM; E and F, 
FC11409B 30 μM; G and H, FC11409B 100 μM. Original magnification of images = x 25. Scale bar = 0.5 mm. B. The effects of S4, 
FC9396A, FC9403A, and FC11409B on the ability of MDA-MB-231 spheroids to invade collagen. Inhibitors were used at 0, 3, 10, 30 and 
100 μM. The invasive areas of each of the spheroids treated with the various concentrations of drug were normalized against the invasion 
area of the control spheroids. Results shown are mean ± SEM, *P < 0.01. n = 8 for all drug concentrations.
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for 5 or 10 days when compared to the Day 0 (start of 
treatment) control. After 10 days treatment, there was 
a significant inhibition of growth in comparison with 
Day 10 control. Similarly, S4 did not reverse invasion 
over this timeline, but after 5 days treatment, there was 
no significant increase in growth in control or treated 
invasive explants (Figure 5C). However by day 10 growth 
of explants treated with 30 μM S4 was significantly 
different from both day 0 and day 10 controls, suggesting 
that although invasive growth was continuing, it was at 
a reduced rate. Interestingly, data for FC9403A indicated 
that growth was not only inhibited, but the invasive 
process was significantly reversed as illustrated in 
Figure 5A. Statistical analysis shows significant decreases 
in the invasive area of these explants after 5 and 10 days 
treatment with FC9403A (Figure 5D).
Because of the heterogeneous nature of the 
human biopsy tissue within the studies shown in 
Figure 5A–5D, and since separate biopsy material 
had been used for each inhibitor, a further experiment 
was performed using explant tissue from the same 
biopsy and the inhibitors compared using 30 μM of 
each inhibitor within the same treatment schedule 
(Figure 5E). This demonstrates that only explants 
treated with FC9403A showed a significant decrease 
in invasive area in comparison with Day 0 controls 
denoting a reversal of the invasive front, while both S4 
and FC9308A have significantly prevented any further 
invasive growth at both time-points when inhibitor-
treated explants are compared with Day 10 and 15 
controls. These results are in accordance those shown 
in Figure 5A–5D.
Figure 3: The effects of S4, FC9398A and FC9403A on breast cancer invasion within an explant invasion assay. A. Breast 
tumor explant invasion assays. Representative experiment showing the ability of FC9403A to inhibit the invasion of an ER+ breast tumor 
explant into collagen after 5 days. Magnification × 25. Scale bar = 0.5 mm. B. Collagen embedded explants showing control invasion 
over 15 days when measured by increased area. Data pooled from 26 separate biopsy samples (n= 214 – 177). Results shown = mean ± 
SEM, ***P < 0.001. C–E. Inhibition of invasion of collagen-embedded explants. C) S4 treatment; D) FC9398A treatment; E) FC9403A 
treatment. Explants were cultured for 15 days with measurements taken every 5 days. Mean ± SEM (n = 8) 21 -25 explants per condition 
*P < 0.05, **P < 0.01, ***P < 0.001 of relevant control
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CAIX expression in a node positive breast 
cancer series
To confirm the relevance of these in vitro and 
in vivo findings, CAIX expression was assessed in a series 
of 92 breast cancer patients with involved lymph nodes 
from which a tissue microarray had been assembled. 
Significantly higher CAIX expression was found in 
triple negative breast cancer subtypes when compared to 
luminal ER+ breast cancers (Supplementary Figure S3), in 
accordance with other studies [11, 12, 28].
CAIX inhibitors limit tumor explant growth 
by decreasing cell proliferation and increasing 
apoptotic cell death
Histological and immunohistochemical examination 
of tumor explants (n = 4) show large numbers of 
invaded cells in the collagen gels (Supplementary 
Figure 4A and 4B) and that S4 (30 and 100 μM) 
(Supplementary Figure 4C and 4D) inhibited invasion. 
Higher cellular CAIX staining was associated with 
invasion (Supplementary Figure 4E and 4F) and the 
Figure 4: The effects of S4, FC9398A and FC9403A, and FC11409B on breast cancer invasion. A. An example of decrease in 
tumor explant area in an invasive explant. Explant treated with 1 μM S4 over 10 days. Magnification × 25. B. Percentage of control explants 
showing invasive morphology over 15 days. Data shown are mean ± SEM (n = 230 explants). ***P < 0.001. C. Percentage of FC9398A 
treated explants showing invasive morphology. Explants cultured for 15 days with measurements taken every 5 days. Inhibitor was used 
at concentrations between 3 – 100 μM. Data shown are mean ± SEM n = 4. ***P < 0.001. D. Percentage of S4 treated explants showing 
invasive morphology . Explants cultured for 15 days with measurements taken every 5 days. Inhibitor was used at concentrations between 
3 – 100 μM. Data shown are mean ± SEM n = 4. ***P < 0.001. E. Percentage of FC9403A treated explants showing invasive morphology . 
Explants cultured for 15 days with measurements taken every 5 days. Inhibitor was used at concentrations between 3– 100 μM. Data shown 
are mean ± SEM n = 4. ***P < 0.001
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majority of invading cells in these explants were clearly 
CAIX positive.
Treatment with S4 decreased the number of CAIX-
positive cells, with staining greatly reduced in explants 
treated with 100 μM S4 compared to controls (compare 
Supplementary Figure S4G and S4H with Supplementary 
Figure S4E and S4F). This suggests that CAIX inhibitors may 
induce cell death in CAIX-positive cells, since S4 treatment 
also increased levels of cleaved caspase 3 expression 
in comparison to untreated control (Supplementary 
Figure S5A–S5F). Tumor regression or stasis may be 
generated via reduced proliferation. Controls revealed higher 
expression of the proliferation marker Ki67 in comparison to 
S4 treated explants, (Supplementary Figure S5G and S5H).
Figure 5: Reversal of invasion in human breast cancer explants after treatment using ureido-sulfamate CAIX 
inhibitors. A. Representative images showing the reversal of invasion in a human breast cancer explant after 5 days of treatment using 
30 μM FC9403A. Explants were monitored for 5 or 10 days and changes quantified using Image J. Original magnification x 25. B. The 
effect of FC9398A on explant invasion. Explants were allowed to invade into collagen plugs for 15 days, before treatment with 30 μM 
FC9398A. Data shown are mean ± SEM. N = 10 *P < 0.05; ***P < 0.001 compared to Day 0 control; ‡‡‡P < 0.001 compared to Day 
10 control. C. The effect of S4 on explant invasion. Explants were allowed to invade into collagen plugs for 15 days, before treatment with 
30 μM S4. Data shown are mean ± SEM. N = 10 − 13 *P < 0.05; **P < 0.05 compared to Day 0 control; + P < 0.05 compared to Day 10 
control. D. The effect of FC9403A on explant invasion. Explants were allowed to invade into collagen plugs for 15 days, before treatment 
with 30 μM FC9403A. Data shown are mean ± SEM. N = 10 − 13 **P < 0.05; ***P < 0.001 compared to Day 0 control. ###P < 0.001 
compared to Day 5 control; +++P < 0.001 compared with Day 10 control. E. Comparison of the effects of S4, FC9398A and FC9403A on 
invasive growth using the same biopsy tissue. Explants were allowed to invade into collagen plugs for 15 days, before treatment with 30 μM 
inhibitor. Data shown are mean ± SD. Samples in triplicate *P < 0.05; ***P < 0.001, compared to Day 0 control; ++P < 0.01; +++P < 0.001 
compared with Day 5 control; ‡‡‡P < 0.001 compared with Day 10 control.
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CAIX inhibitors slow tumor growth in vivo by 
decreasing cell proliferation and increasing 
cell death
Pharmacokinetic data (unpublished data-personal 
communication Erik Pettersen) indicated that FC9398A 
and a novel nitroimidazole based sulfamide CAIX 
inhibitor, DTP348 had better in vivo stability, with positive 
results in HT-29 colorectal xenograft models [26, 27]; 
(DTP348 structure is shown in [27]). MDA-MD-231 
xenografts were therefore used to examine the in vivo 
effects of CAIX inhibition in breast cancer. Figure 6A 
illustrates that both these compounds could reduce 
relative tumor volume when used alone. Interestingly, 
although these two compounds had similar effects on 
tumor volume, only DTP348 significantly decreased Ki67 
expression and reduced the percentage of viable cells 
in the xenograft model (Figures 6B and 6C). Figure 6D 
illustrates the extent and location of CAIX-positive cells 
in an untreated MDA-MB-231 xenograft.
DISCUSSION
This study validates the pH regulator CAIX as a 
strong therapeutic candidate with potential effectiveness 
in treatment of breast cancer, including TNBC, and as far 
as we are aware, is the first report to show the preclinical 
efficacy of CAIX inhibition in human breast cancer tissue 
from various breast cancer subtypes, thus potentially 
helping to fill critical gaps in breast cancer treatment 
as previously outlined [1]. The effectiveness of several, 
novel, specific inhibitors was determined in a number of 
biological assays using both 2D and 3D cell and tissue 
models. We clearly demonstrate that these compounds 
can significantly inhibit and prevent breast cancer cell 
proliferation and invasion in a dose-dependent manner. 
Furthermore, the compound, FC9403A, could significantly 
reverse established invasion of ex-vivo collagen embedded 
fresh breast cancer biopsy material. The mechanisms 
involved in these effects depend on loss of proliferation 
and increased apoptosis of CAIX-positive cells.
Presently, there is a compelling requirement for 
better methods to control and treat metastatic disease, 
particularly in breast, lung and testicular cancers, which 
have greater metastatic potential than other malignancies 
[1, 29, 30]. In a murine knock down model, CAIX 
deficiency had no effect on growth, reproduction, health 
or lifespan of mice in comparison with wild type controls, 
and no morphologic or histologic effects other than gastric 
hyperplasia in targeted mice were observed [31, 32]. This 
suggests that inhibition of CAIX function should have 
limited toxicity in normal tissue supporting its potential as 
an anticancer therapy.
2D cultures demonstrated significant inhibition of 
cell proliferation in both normoxic and hypoxic conditions. 
In agreement with these results, an earlier study using 
RNAi, to decrease CAIX expression, found significant 
effects on growth and survival under both normoxic and 
hypoxic conditions in breast cancer cells [33]. Because 
oncogenic changes can stabilize HIF expression in 
normoxic cancer cells, [5, 6], CAIX expression can be 
increased in normoxic conditions in breast cancer cell 
lines (Supplementary Figure S2). A previous report 
has suggested that ureido-sulfamate inhibitors may 
preferentially target active CAIX [34], which may explain 
the more potent effect of these inhibitors in hypoxia, where 
CAIX activity would increase as cells become more reliant 
on glycolysis. Although others have described CAIX as 
being present only in the hypoxic cores of 3D spheroids 
[17], CAIX is clearly expressed independently of hypoxia 
and is not confined to the hypoxic peri-necrotic areas of 
breast cancer cell spheroids (Supplementary Figure S2). 
This may explain the effectiveness of these compounds in 
normoxic conditions in 2D assays, since some expression 
is clearly independent of oxygen concentration.
Wound healing assays illustrated the potential of 
4 of these novel compounds, S4, FC11409B, FC9398A 
and FC9403A to effectively hinder migration of breast 
and ovarian cancer cells in both normoxic and hypoxic 
conditions (Supplementary Figure S1A–S1D). The 
C-terminal intracellular tail of CAIX is regulated by 
phosphorylation of Thr443 by PKA; this transmits 
signals to the extracellular enzyme domain in hypoxic 
conditions and influences cell migration [35, 36]. CAIX 
also increases cell migration and invasion in vitro via 
transcriptional activation and modulation of proteins 
involved in cytoskeletal reorganisation and EMT [23]. 
It has been postulated that CAIX interacts with the 
secreted protein DKK1 and interferes with the Rho/
ROCK signaling pathway causing activation of paxillin, 
which promotes dynamic adhesion turnover and migration 
[23]. Interestingly, this Rho/ROCK pathway is pH 
sensitive [37, 38].
Spheroid invasion assays illustrated the potential of 
these CAIX inhibitors to hinder invasion and further, at 
higher concentrations, prevent it. Interestingly, the most 
invasive spheroids are those formed from MDA-MD-231 
cells and as shown in Supplementary Figure S2C, these 
have extremely high CAIX expression. Using tumor 
explants from treatment naïve breast cancer patients, we 
confirmed that the inhibitors S4, FC9398A and FC9403A 
could inhibit and prevent metastatic invasion of collagen 
plugs using several methods of analysis (Figures 3 and 4). 
In addition, all these compounds could prevent further 
invasive growth of established explants and in the case 
of FC9403A, could significantly reverse invasive growth 
(Figure 5D and 5E). The majority of invasive cells from 
the explants were positive for CAIX expression. Treatment 
with inhibitory compounds increased the expression of 
cleaved caspase-3, while concomitantly reducing the 
expression of Ki67 and CAIX. Decreased expression 
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of CAIX in treated explants implies that CAIX positive 
cells have been selectively removed, suggesting that 
apoptosis had been induced in cells expressing CAIX and 
that proliferation decreased in treated explants. Because 
FC9403A not only effectively inhibited tumor growth 
and invasion, but also reversed established invasive 
growth, the method involved in preventing invasion 
is not dependent on inhibition of metalloproteinases; 
supporting the involvement of apoptosis in removal of the 
invading cells.
Analysis of CAIX in a series of breast cancer 
patients with axillary node metastases showed that 
higher CAIX expression correlated with HER2 positive 
and triple negative breast cancer, which are prone to be 
more aggressive and metastatic. Several studies support 
a role for CAIX in breast cancer invasion and lymph 
node metastasis [11, 12, 39]. For example, IL-6/Notch-3 
signaling increases CAIX expression and stimulates 
breast cancer cell invasion [40, 41] and HER2+ and 
triple negative breast cancers which express CAIX are 
associated with poor prognosis and high levels of early 
metastases to bone, lung and brain [42].
In vivo xenograft work, additionally demonstrated 
that these novel CAIX inhibitors can slow tumor growth 
by a mechanism involving decreased proliferation and 
loss of viability. This is supported by studies in a colon 
cancer model, where overexpression of CAIX amplified 
the growth rate of 3D spheroids and xenografts, but also 
increased necrosis, apoptosis and proliferation [43]. 
Increased growth caused greater areas of hypoxia in the 
core of the 3D structures, which would account for higher 
levels of cell death. This study also demonstrated that 
the area of viable tissue increased with CAIX expression 
[43]. CAIX knockdown has been shown to increase tumor 
Figure 6: The effects of DTP348 and FC9398A on the MDA-MB-231 breast cancer xenograft model. A. The effect of 
DTP348 and FC9398A on relative mean tumor volume of MDA-MB-231 breast cancer xenografts. 10 mice were used per treatment and 
tumors measured over a 14 day period. Data shown are mean ± SD. *p < 0.05 compared with day matched control. B. Ki67 expression in 
xenografts collected on final day (Day 14) of study. Mean values of approximately 2000 cells counted from multiple fields. C. Percentage 
viability in treated xenografts was assessed by use of Image J software on hematoxylin stained sections. D. CAIX staining in an untreated 
MDA-MB-231 xenograft. Magnification X25. Brown cellular areas indicate CAIX expression. Light brown acellular areas are areas of 
necrosis. Cells were stained with hematoxylin (blue).
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regression, survival and relapse in a murine metastatic 
breast cancer model. Furthermore this strategy virtually 
eliminated metastatic growth [39]. The CAIX inhibitor 
S4, has also shown anti-metastatic capabilities in a 
murine model using the MDA-MB-231 breast cancer cell 
line [25].
Our data supports the premise that CAIX plays an 
essential role in the invasive and metastatic processes 
involved in breast cancer progression using several model 
systems. Importantly, this study shows in ex vivo assays 
using live human breast cancer tissue, that CAIX is a 
relevant therapeutic target for breast cancer treatment. 
As far as we are aware, this is the first report of this 
type, using live cultured ex vivo breast cancer tissue 
for a period of 25 days Recent work demonstrated that 
tumor grafts from breast cancer patients cultured in mice, 
accurately replicate tumor growth, metastatic potential 
and pathology of the major breast cancer classifications 
[44], and importantly, conserve the histological markers 
and features of the original tumor such as HER2 and ER 
positivity, as well as proliferation indices [45].
The explant ex vivo model reported herein, conserves 
many aspects of the original tumor pathophysiology and 
is therefore is more relevant for oncology drug trials, 
particularly those involving microenvironmental targets 
and further allows the influences of stromal elements 
on drug responses to be assessed. It not only reflects the 
heterogeneous nature of breast tumors per se, but also the 
heterogeneous nature of the disease, since biopsies from 
all major breast cancer subtypes were available for use in 
this study, suggesting that these CAIX inhibitors could be 
beneficial in all types of breast cancer.
Our results using these CAIX inhibitory compounds 
are supported by other recent findings reporting decreases 
in both primary tumor growth and metastasis in several 
preclinical breast tumor models with no signs of non-
specific toxicity [25, 40, 46]. One CAIX inhibitor, 
Indisulam, is currently in Phase II clinical trials treating 
various tumor types, including stage IV melanoma, renal 
clear cell carcinoma, lung, pancreatic and metastatic breast 
cancer [47]. Our data clearly show that inhibition of CAIX 
using these novel ureido-sulfamate compounds influences 
both the proliferation/cell death and migration and 
invasion of human breast cancer cells. CAIX is therefore 
an attractive target for breast cancer treatment.
MATERIALS AND METHODS
Cell lines and culture
The cell lines used in this study, their receptor 
expression and breast cancer subtype are shown in 
Supplementary Table S1. Human breast cancer lines were 
cultured in DMEM supplemented with 10% fetal calf 
serum and 1% penicillin/streptomycin in normoxic (21%) 
or hypoxic (0.5%) O2 concentrations in a Don Whitley 
Hypoxystation H35 Workstation. MCF 10A cells were 
cultured in DMEM/F12, supplemented with donor horse 
serum (5%), epidermal growth factor (20 ng/ml) 
hydrocortisone (0.5 μg/ml), cholera toxin (100 ng/ml) 
insulin (10 μg/ml) and 1% penicillin/streptomycin. All 
cell lines were purchased from ATTC and tested and 
authenticated using STR profiling by Public Health 
England, Porton Down, Salisbury, UK, (November 2014).
Sulforhodamine B assay
Cells were plated (1 × 103/200 μl media) in 96-
well plates and treated after 48 hours. At appropriate 
times, wells were fixed with 50 μl 25% trichloroacetic 
acid, washed with H2O and dried before addition of SRB 
(50 μl). After 30 minutes, plates were washed with 1% 
acetic acid. When dry, 150 μl of SRB assay buffer (10 mM 
Tris pH10.5), was added per well for 1 hour before reading 
at 540 nm on a Biohit BP800 platereader.
Wounding/invasion assay
Cells (MDA-MB-231 or SKOV3 (5 × 105/well)) 
were grown in 6-well plates until confluent. After 
wounding with a sterile tip, media containing 0.2% serum 
and the drug of interest were added. Invasion/migration of 
cells was calculated by comparison of the scratch at time 
‘0′ and after 24 or 48 hours. The extent of migration of the 
SKOV3 cells was determined by analyzing the percentage 
of closed wound area, measured using DatInf Measure 
setup Wizard software.
3D cell culture
Cells were incubated in spinner flasks and cultured 
at 37°C in 5% CO2 until spheroids formed. Growth 
of live cells in 3D culture was monitored by adding 
a 10 μM solution of Cell Tracker Green CMFDA 
(5-chloromethylfluorescein diacetate) to a sample of 
spheroids for 45 minutes at 37°C. After washing, fresh 
media was applied for 30 minutes before checking growth 
using a fluorescent microscope.
3D invasion studies using breast tumor spheroids 
or human breast cancer biopsy explants
The collection of fresh breast tumor biopsy material 
received local ethical approval from the Lothian Tissue 
Governance Committee (10/S1402/33). Informed 
consent from patients for the collection and use of 
tissue samples was obtained prior to use. Breast tumor 
biopsy material was trimmed and cut into 1mm3 pieces. 
Collagen type I (Wako Chemicals) was mixed with 1:1000 
filtered acetic acid, DMEM/F12 (X 10) and 0.22M NaOH 
in a ratio of 3:5:1:1 (final collagen concentration of 0.3 mg/
ml). Compounds in collagen were added to 24-well plate 
(0.5 ml/well) and 1 piece of tissue added. After incubation 
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at 37°C for 1 hour to solidify the collagen, 500 μl of 
MEGM complete media (Lonza, Switzerland) containing 
compound was added per well. Treatments continued for 
up to 15 days. At termination of experiments, cultures 
were fixed in 10% phosphate buffered formalin, wax 
embedded, and processed for immunohistochemistry. 
3D spheroid invasion assays were performed in the same 
manner except that DMEM culture media (prepared as 
above) was used, and experiments terminated by 48 hours. 
Results were quantified using Image J Software.
Immunohistochemistry
Embedded sections from spheroids or tumor 
explants were dewaxed and antigen retrieval performed 
before washing and blocking for 10 minutes. After 
washing, slides were incubated with primary antibody for 
1 hour at room temperature or overnight at 4°C, before 
washing. Slides were incubated with Dako Envision 
labelled polymer for 30 minutes, washed and treated with 
DAB substrate, before counterstaining with haematoxylin.
Tissue microarray (TMA)
Tissue samples originated from patients with 
primary breast carcinomas treated in the Edinburgh 
Breast Unit between 1999 and 2002. The study received 
local ethical approval from the Lothian Research Ethics 
Committee (08/S1101/41). No informed consent (written 
or verbal) was obtained for use of retrospective tissue 
samples from the patients within this study, most of 
whom were deceased, as this was not deemed necessary 
by the Ethics Committee. Axillary lymph node dissection 
was performed on all patients as part of surgery for 
large or high-grade invasive breast carcinomas and 
extracted tissues embedded into a recipient paraffin 
block in a uniformly spaced array pattern for further 
analysis. TMAs were constructed in biological triplicate. 
Ninety-two cancers were available for analysis after 
TMA construction, immunostaining, AQUAsition, and 
AQUAnalysis as detailed in previous work [48].
Xenograft studies
The xenograft studies were undertaken under a 
UK Home Office Project Licence in accordance with the 
Animals (Scientific Procedures) Act 1986 and studies were 
approved by the University of Edinburgh Animal Ethics 
Committee. Adult female nu/nu mice were implanted 
subcutaneously into both flanks with MDA-MB-231 
tumor fragments (previously established from the cell 
line) and groups of tumors grown to 4–6 mm diameter 
over a period of approximately 1 month. Animals were 
allocated to treatment or control groups (10 mice/group) 
and treatment commenced (defined as day 0). DTP348 
(10 mg/kg/day) or FC398A (25mg/kg/day) were given via 
the intraperitoneal route in saline on days 0–4. Tumor size 
was measured twice weekly using calipers and the volume 
calculated according to the formula π/6 × length × width2. 
Relative tumor volumes (%) were calculated for each 
individual tumor by dividing the tumor volume on day t 
(Vt) by the tumor volume on day 0 (V0) and multiplying 
by 100. Tumors were excised and dissected (50% snap 
frozen in liquid nitrogen; 50% placed into formalin 
saline for 24 hours) before embedding in paraffin. Ki67 
expression was evaluated by immunohistochemistry. Ten 
fields per xenograft section were evaluated via Image J.
Statistical analysis
Data was analysed by ANOVA followed by Tukey-
Kramer multiple comparison test; a P value of < 0.05 was 
considered statistically significant.
Other materials
Cell Tracker Green CMFDA (5-Chloromethyl 
fluorescein Diacetate) was obtained from Invitrogen (UK). 
HIF-1α antibody was obtained from BD Biosciences 
(610958); CAIX and NHE1 from Novus Biologicals 
(NB100-417, and NBP1-20198, respectively); CAIX 
from Bioscience Slovakia (clone M75; Ki67 from Dako 
(M7240); cleaved caspase-3 from Cell Signalling (9661); 
Hypoxyprobe-1 Kit from Hypoxyprobe Inc. All antibodies 
were validated by western blot to confirm the absence of 
non-specific bands. The novel ureido-sulfamate CAIX 
inhibitors FC11409B, FC9398A, FC9403, FC9396A and S4 
were synthesized as previously detailed [24, 25]. DTP was 
synthesized as previously described [26].
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